Isthmus Partners LLC Decreases Position in OmniAb, Inc. (NASDAQ:OABI)

Isthmus Partners LLC trimmed its position in shares of OmniAb, Inc. (NASDAQ:OABI) by 15.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 446,134 shares of the company’s stock after selling 82,251 shares during the quarter. Isthmus Partners LLC owned approximately 0.38% of OmniAb worth $1,887,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Palumbo Wealth Management LLC lifted its position in shares of OmniAb by 12.5% in the third quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company’s stock valued at $104,000 after acquiring an additional 2,744 shares in the last quarter. Sei Investments Co. lifted its position in shares of OmniAb by 11.0% in the second quarter. Sei Investments Co. now owns 29,024 shares of the company’s stock valued at $109,000 after acquiring an additional 2,888 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of OmniAb by 13.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 26,843 shares of the company’s stock valued at $146,000 after acquiring an additional 3,108 shares in the last quarter. Simplicity Wealth LLC lifted its position in shares of OmniAb by 23.3% in the second quarter. Simplicity Wealth LLC now owns 42,160 shares of the company’s stock valued at $158,000 after acquiring an additional 7,976 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of OmniAb by 64.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company’s stock valued at $96,000 after acquiring an additional 8,909 shares in the last quarter. 72.08% of the stock is currently owned by hedge funds and other institutional investors.

OmniAb Price Performance

Shares of NASDAQ OABI opened at $3.90 on Friday. OmniAb, Inc. has a 1-year low of $3.56 and a 1-year high of $6.72. The business has a 50-day moving average of $4.10 and a 200-day moving average of $4.23. The company has a market capitalization of $550.76 million, a price-to-earnings ratio of -6.29 and a beta of -0.12.

Analyst Upgrades and Downgrades

OABI has been the subject of several analyst reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $7.00 target price on shares of OmniAb in a research note on Friday, August 16th. HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of OmniAb in a research note on Thursday, November 14th. Finally, Benchmark reaffirmed a “buy” rating and issued a $8.00 target price on shares of OmniAb in a research report on Thursday, November 14th.

OmniAb Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.